117 related articles for article (PubMed ID: 23499651)
1. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds.
Rhoden E; Liu HM; Wang-Chern SW; Oberste MS
Antiviral Res; 2013 May; 98(2):186-91. PubMed ID: 23499651
[TBL] [Abstract][Full Text] [Related]
2. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
[TBL] [Abstract][Full Text] [Related]
3. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
[TBL] [Abstract][Full Text] [Related]
4. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.
Liu HM; Roberts JA; Moore D; Anderson B; Pallansch MA; Pevear DC; Collett MS; Oberste MS
Antimicrob Agents Chemother; 2012 Nov; 56(11):5568-74. PubMed ID: 22890765
[TBL] [Abstract][Full Text] [Related]
5. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
Thys B; De Palma AM; Neyts J; Andries K; Vrijsen R; Rombaut B
Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707
[TBL] [Abstract][Full Text] [Related]
6. A case for developing antiviral drugs against polio.
Collett MS; Neyts J; Modlin JF
Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity.
Schotte L; Strauss M; Thys B; Halewyck H; Filman DJ; Bostina M; Hogle JM; Rombaut B
J Virol; 2014 Apr; 88(8):4403-13. PubMed ID: 24501405
[TBL] [Abstract][Full Text] [Related]
9. Antipoliovirus activity and mechanism of action of 3-methylthio-5-phenyl-4-isothiazolecarbonitrile.
Garozzo A; Stivala A; Tempera G; Castro A
Antiviral Res; 2010 Dec; 88(3):325-8. PubMed ID: 20955736
[TBL] [Abstract][Full Text] [Related]
10. Identification and Analysis of Antiviral Compounds Against Poliovirus.
Leyssen P; Franco D; Tijsma A; Lacroix C; De Palma A; Neyts J
Methods Mol Biol; 2016; 1387():325-38. PubMed ID: 26983743
[TBL] [Abstract][Full Text] [Related]
11. Dominant drug targets suppress the emergence of antiviral resistance.
Tanner EJ; Liu HM; Oberste MS; Pallansch M; Collett MS; Kirkegaard K
Elife; 2014 Nov; 3():. PubMed ID: 25365453
[TBL] [Abstract][Full Text] [Related]
12. New class of early-stage enterovirus inhibitors with a novel mechanism of action.
Ma Y; Abdelnabi R; Delang L; Froeyen M; Luyten W; Neyts J; Mirabelli C
Antiviral Res; 2017 Nov; 147():67-74. PubMed ID: 28993161
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.
Salvati AL; De Dominicis A; Tait S; Canitano A; Lahm A; Fiore L
Antimicrob Agents Chemother; 2004 Jun; 48(6):2233-43. PubMed ID: 15155227
[TBL] [Abstract][Full Text] [Related]
14. Poliovirus infection without accumulation of eclipse particles.
Ofori-Anyinam O; Vrijsen R; Kronenberger P; Boeyé A
Antiviral Res; 1995 Jan; 26(1):27-35. PubMed ID: 7741519
[TBL] [Abstract][Full Text] [Related]
15. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.
McKinlay MA; Collett MS; Hincks JR; Oberste MS; Pallansch MA; Okayasu H; Sutter RW; Modlin JF; Dowdle WR
J Infect Dis; 2014 Nov; 210 Suppl 1():S447-53. PubMed ID: 25316866
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a rare natural intertypic type 2/type 3 penta-recombinant vaccine-derived poliovirus isolated from a child with acute flaccid paralysis.
Zhang Y; Wang H; Zhu S; Li Y; Song L; Liu Y; Liu G; Nishimura Y; Chen L; Yan D; Wang D; An H; Shimizu H; Xu A; Xu W
J Gen Virol; 2010 Feb; 91(Pt 2):421-9. PubMed ID: 19846676
[TBL] [Abstract][Full Text] [Related]
17. Potential use of antiviral agents in polio eradication.
De Palma AM; Pürstinger G; Wimmer E; Patick AK; Andries K; Rombaut B; De Clercq E; Neyts J
Emerg Infect Dis; 2008 Apr; 14(4):545-51. PubMed ID: 18394270
[TBL] [Abstract][Full Text] [Related]
18. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania.
Combiescu M; Guillot S; Persu A; Baicus A; Pitigoi D; Balanant J; Oprisan G; Crainic R; Delpeyroux F; Aubert-Combiescu A
Arch Virol; 2007; 152(4):727-38. PubMed ID: 17195957
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of Poliovirus Resistance to Host Phosphatidylinositol-4 Kinase III β Inhibitor.
Arita M
ACS Infect Dis; 2016 Feb; 2(2):140-8. PubMed ID: 27624965
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the poliovirus P1 capsid precursor at arginine residues VP4-ARG34, VP3-ARG223, and VP1-ARG129 affect virus assembly and encapsidation of genomic RNA.
Ansardi DC; Luo M; Morrow CD
Virology; 1994 Feb; 199(1):20-34. PubMed ID: 8116243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]